ACE 393

Drug Profile

ACE 393

Alternative Names: ACE-393; Campylobacter jejuni vaccine - Zymenex

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator ACE BioSciences
  • Developer ACE BioSciences; Naval Medical Research Center
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Campylobacter infections

Most Recent Events

  • 21 Mar 2014 Discontinued - Phase-II for Campylobacter infections in USA & Phase I for Campylobacter infections in France (IM)
  • 18 Jan 2011 No development reported - Phase-II for Campylobacter infections in USA (IM)
  • 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top